<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02216838</url>
  </required_header>
  <id_info>
    <org_study_id>STU97514</org_study_id>
    <nct_id>NCT02216838</nct_id>
  </id_info>
  <brief_title>Treatment of Facial Flushing With Botulinum Toxin A Injections</brief_title>
  <official_title>Treatment of Facial Flushing With Botulinum Toxin A Injections: A Split-Face, Double-blinded, Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if botulinum toxin A (botoxÂ®) can be used to treat
      facial flushing.

      This study is a pilot study designed to determine feasibility of these procedures.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spectrophotometer measurement</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Spectrophotometer measurement as the percent resolution on each follow up visit compared to baseline visit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Facial Flushing</condition>
  <arm_group>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This study is randomized, which means the subject will be randomly assigned (like a flip of a coin) to receive botox on the right or left side of the face and saline injections on the other side. Only one side of the face will receive botox injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin A</intervention_name>
    <description>A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.</description>
    <arm_group_label>botulinum toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline Control</intervention_name>
    <description>A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side</description>
    <arm_group_label>Saline Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18-65 years of age with persistent facial flushing

          2. Willing and have the ability to understand and provide informed consent for
             participation in the study and are able to communicate with the study staff.

        Exclusion Criteria:

          1. Unable to understand the protocol or give informed consent

          2. Younger than 18 or older than 65 years of age

          3. Females who are pregnant or lactating

          4. Known hypersensitivity to BTX-A

          5. Subjects using medications that interfere with neuromuscular functions (such as
             aminoglycoside antibiotics)

          6. Subjects who have a history of congestive heart failure, carcinoid syndrome,
             mastocystosis, or renal cell carcinoma

          7. Botulinum toxin injections in the past 6 months

          8. Ablative laser procedure in the past 6 months

          9. Radiofrequency device treatment in the past 6 months

         10. Ultrasound device treatment in the past 6 months

         11. Medium to deep chemical peel in the past 6 months

         12. Temporary soft tissue augmentation material in the area to be treated in the past year

         13. Semi-permanent soft tissue augmentation material in the area to be treated in the past
             2 years

         14. Permanent soft tissue augmentation material in the area to be treated

         15. Is planning to receive within the next 6 months, any cosmetic procedure (such as any
             chemical peels, botulinum toxin injections, ablative or non-ablative laser procedures,
             filler injections, radiofrequency procedures, dermabrasion, ultrasound and face
             lifting procedures) in the forehead or glabellar region.

         16. Is planning to use tretinoin or retinoic acid in the next 6 months

         17. Has an active infection in the forehead or glabellar region (excluding mild acne)

         18. Is allergic to cow's milk protein

         19. Is allergic to albumin

         20. Is currently using anticoagulation therapy

         21. Has a history of bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murad Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine, Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2014</study_first_submitted>
  <study_first_submitted_qc>August 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Murad Alam</investigator_full_name>
    <investigator_title>Professor in Dermatology, Otolaryngology-Head and Neck Surgery, and Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

